Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial

Peter Carson, S. William Tam, Jalal K. Ghali, W. Tad Archambault, Anne Taylor, Jay N Cohn, Virginia M. Braman, Manuel Worcel, Inder Anand

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: To characterize the quality of life (QOL) in the African-American Heart Failure Trial (A-HeFT) for factors associated with baseline score, relation of score to prognosis, and response to therapy with a fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H). Limited data exist on QOL scores in African-American heart failure patients or on the prognostic value of theses scores in any population. Finally, the effect of FDC I/H on QOL scores, particularly in A-HeFT, is not known. Methods and Results: A-HeFT randomized 1050 African-American patients with New York Heart Association (NYHA) Class III-IV heart failure and systolic dysfunction. QOL measurements using Minnesota Living with Heart Failure Questionnaire (MLHFQ) were done at baseline and 3-month intervals. At baseline, worse MLHFQ scores were associated with younger age, female sex, greater body mass index, nonischemic etiology, high heart rate and NYHA Class, low systolic blood pressure, and chronic obstructive pulmonary disease. Both baseline and change in MLHFQ score were associated with a higher risk for combined all-cause mortality or heart failure hospitalization (baseline P < .0001, change at 3 months P = .001, and at 6 months P = .0008), but not mortality. Treatment with FDC I/H significantly improved MLHFQ score compared with placebo. Conclusions: In A-HeFT, baseline QOL (MLHFQ) scores and change in score were predictive of combined HF morbidity and mortality outcomes. FDC I/H consistently improved QOL scores in A-HeFT compared with placebo.

Original languageEnglish (US)
Pages (from-to)835-842
Number of pages8
JournalJournal of Cardiac Failure
Volume15
Issue number10
DOIs
StatePublished - Dec 1 2009

Fingerprint

African Americans
Heart Failure
Quality of Life
Mortality
Placebos
Systolic Heart Failure
Hypotension
Chronic Obstructive Pulmonary Disease
Hospitalization
Body Mass Index
Heart Rate
Surveys and Questionnaires
Blood Pressure
Morbidity
isosorbide-hydralazine combination

Keywords

  • Heart failure
  • morbidity
  • nitric oxide
  • quality of life
  • race

Cite this

Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. / Carson, Peter; Tam, S. William; Ghali, Jalal K.; Archambault, W. Tad; Taylor, Anne; Cohn, Jay N; Braman, Virginia M.; Worcel, Manuel; Anand, Inder.

In: Journal of Cardiac Failure, Vol. 15, No. 10, 01.12.2009, p. 835-842.

Research output: Contribution to journalArticle

Carson, Peter ; Tam, S. William ; Ghali, Jalal K. ; Archambault, W. Tad ; Taylor, Anne ; Cohn, Jay N ; Braman, Virginia M. ; Worcel, Manuel ; Anand, Inder. / Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. In: Journal of Cardiac Failure. 2009 ; Vol. 15, No. 10. pp. 835-842.
@article{6d753a7d3cb94a8a809db7ada3a96c15,
title = "Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial",
abstract = "Background: To characterize the quality of life (QOL) in the African-American Heart Failure Trial (A-HeFT) for factors associated with baseline score, relation of score to prognosis, and response to therapy with a fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H). Limited data exist on QOL scores in African-American heart failure patients or on the prognostic value of theses scores in any population. Finally, the effect of FDC I/H on QOL scores, particularly in A-HeFT, is not known. Methods and Results: A-HeFT randomized 1050 African-American patients with New York Heart Association (NYHA) Class III-IV heart failure and systolic dysfunction. QOL measurements using Minnesota Living with Heart Failure Questionnaire (MLHFQ) were done at baseline and 3-month intervals. At baseline, worse MLHFQ scores were associated with younger age, female sex, greater body mass index, nonischemic etiology, high heart rate and NYHA Class, low systolic blood pressure, and chronic obstructive pulmonary disease. Both baseline and change in MLHFQ score were associated with a higher risk for combined all-cause mortality or heart failure hospitalization (baseline P < .0001, change at 3 months P = .001, and at 6 months P = .0008), but not mortality. Treatment with FDC I/H significantly improved MLHFQ score compared with placebo. Conclusions: In A-HeFT, baseline QOL (MLHFQ) scores and change in score were predictive of combined HF morbidity and mortality outcomes. FDC I/H consistently improved QOL scores in A-HeFT compared with placebo.",
keywords = "Heart failure, morbidity, nitric oxide, quality of life, race",
author = "Peter Carson and Tam, {S. William} and Ghali, {Jalal K.} and Archambault, {W. Tad} and Anne Taylor and Cohn, {Jay N} and Braman, {Virginia M.} and Manuel Worcel and Inder Anand",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.cardfail.2009.05.016",
language = "English (US)",
volume = "15",
pages = "835--842",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "10",

}

TY - JOUR

T1 - Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial

AU - Carson, Peter

AU - Tam, S. William

AU - Ghali, Jalal K.

AU - Archambault, W. Tad

AU - Taylor, Anne

AU - Cohn, Jay N

AU - Braman, Virginia M.

AU - Worcel, Manuel

AU - Anand, Inder

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: To characterize the quality of life (QOL) in the African-American Heart Failure Trial (A-HeFT) for factors associated with baseline score, relation of score to prognosis, and response to therapy with a fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H). Limited data exist on QOL scores in African-American heart failure patients or on the prognostic value of theses scores in any population. Finally, the effect of FDC I/H on QOL scores, particularly in A-HeFT, is not known. Methods and Results: A-HeFT randomized 1050 African-American patients with New York Heart Association (NYHA) Class III-IV heart failure and systolic dysfunction. QOL measurements using Minnesota Living with Heart Failure Questionnaire (MLHFQ) were done at baseline and 3-month intervals. At baseline, worse MLHFQ scores were associated with younger age, female sex, greater body mass index, nonischemic etiology, high heart rate and NYHA Class, low systolic blood pressure, and chronic obstructive pulmonary disease. Both baseline and change in MLHFQ score were associated with a higher risk for combined all-cause mortality or heart failure hospitalization (baseline P < .0001, change at 3 months P = .001, and at 6 months P = .0008), but not mortality. Treatment with FDC I/H significantly improved MLHFQ score compared with placebo. Conclusions: In A-HeFT, baseline QOL (MLHFQ) scores and change in score were predictive of combined HF morbidity and mortality outcomes. FDC I/H consistently improved QOL scores in A-HeFT compared with placebo.

AB - Background: To characterize the quality of life (QOL) in the African-American Heart Failure Trial (A-HeFT) for factors associated with baseline score, relation of score to prognosis, and response to therapy with a fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H). Limited data exist on QOL scores in African-American heart failure patients or on the prognostic value of theses scores in any population. Finally, the effect of FDC I/H on QOL scores, particularly in A-HeFT, is not known. Methods and Results: A-HeFT randomized 1050 African-American patients with New York Heart Association (NYHA) Class III-IV heart failure and systolic dysfunction. QOL measurements using Minnesota Living with Heart Failure Questionnaire (MLHFQ) were done at baseline and 3-month intervals. At baseline, worse MLHFQ scores were associated with younger age, female sex, greater body mass index, nonischemic etiology, high heart rate and NYHA Class, low systolic blood pressure, and chronic obstructive pulmonary disease. Both baseline and change in MLHFQ score were associated with a higher risk for combined all-cause mortality or heart failure hospitalization (baseline P < .0001, change at 3 months P = .001, and at 6 months P = .0008), but not mortality. Treatment with FDC I/H significantly improved MLHFQ score compared with placebo. Conclusions: In A-HeFT, baseline QOL (MLHFQ) scores and change in score were predictive of combined HF morbidity and mortality outcomes. FDC I/H consistently improved QOL scores in A-HeFT compared with placebo.

KW - Heart failure

KW - morbidity

KW - nitric oxide

KW - quality of life

KW - race

UR - http://www.scopus.com/inward/record.url?scp=70450225256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450225256&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2009.05.016

DO - 10.1016/j.cardfail.2009.05.016

M3 - Article

VL - 15

SP - 835

EP - 842

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 10

ER -